Brief: Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics

26/03/2025 20:16

March 26 (Reuters) - Candel Therapeutics Inc CADL.O:

CANDEL THERAPEUTICS REPORTS BOTH PROLONGED MEDIAN OVERALL SURVIVAL AND LONG TAIL OF SURVIVAL IN PHASE 2A CLINICAL TRIAL OF CAN-2409 IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS NON-RESPONSIVE TO IMMUNE CHECKPOINT INHIBITOR (ICI) TREATMENT

CANDEL THERAPEUTICS: STATISTICALLY SIGNIFICANT IMPROVED OVERALL SURVIVAL IN NON-SQUAMOUS NSCLC VERSUS SQUAMOUS NSCLC AFTER CAN-2409 EXPERIMENTAL TREATMENT

CANDEL THERAPEUTICS INC:  CAN-2409 CONTINUED TO EXHIBIT A GENERALLY FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGHOUT EXTENDED FOLLOW-UP PERIOD

Source text: ID:nGNXb6Qg9D

Further company coverage: CADL.O

 ((Reuters.Briefs@thomsonreuters.com;))